BRD2 and ovarian hyperstimulation syndrome: The current therapeutic strategies include sex hormone therapy such as follicle-stimulating hormone (FSH) therapy, human chorionic gonadotropin, estrogen replacement therapy, etc., assisted reproductive technology, and tubal plastic surgery which despite some desired advances, these strategies are invasive, expensive, and are faced with unavoidable adverse effects like increasing the risk of ovarian hyperstimulation syndrome (OHSS), mental disorders, and so on [1][12][13].